JP2005538187A - 新規キヌクリジン誘導体及びその使用方法 - Google Patents
新規キヌクリジン誘導体及びその使用方法 Download PDFInfo
- Publication number
- JP2005538187A JP2005538187A JP2005502013A JP2005502013A JP2005538187A JP 2005538187 A JP2005538187 A JP 2005538187A JP 2005502013 A JP2005502013 A JP 2005502013A JP 2005502013 A JP2005502013 A JP 2005502013A JP 2005538187 A JP2005538187 A JP 2005538187A
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- alkyl
- octane
- aza
- bicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 150000008584 quinuclidines Chemical class 0.000 title abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 100
- 150000001875 compounds Chemical class 0.000 claims abstract description 86
- 201000010099 disease Diseases 0.000 claims abstract description 57
- 208000035475 disorder Diseases 0.000 claims abstract description 43
- 239000000126 substance Substances 0.000 claims abstract description 13
- 208000002193 Pain Diseases 0.000 claims abstract description 11
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 11
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract description 9
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000016160 smooth muscle contraction Effects 0.000 claims abstract description 7
- -1 cycloalkoxy-alkoxy Chemical group 0.000 claims description 149
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 claims description 61
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 39
- 125000002950 monocyclic group Chemical group 0.000 claims description 37
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000003367 polycyclic group Chemical group 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 32
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000002837 carbocyclic group Chemical group 0.000 claims description 31
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 27
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 26
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 23
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 23
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 22
- 150000001408 amides Chemical class 0.000 claims description 20
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 11
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 11
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- UYDJFXWILYZAEM-UHFFFAOYSA-N 3-(6-bromopyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound N1=NC(Br)=CC=C1OC1C(CC2)CCN2C1 UYDJFXWILYZAEM-UHFFFAOYSA-N 0.000 claims description 7
- 125000003118 aryl group Chemical class 0.000 claims description 7
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 6
- SURCGQGDUADKBL-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(NCCO)C2=O)=O)=C3C2=CC=CC3=C1 SURCGQGDUADKBL-UHFFFAOYSA-N 0.000 claims description 6
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 6
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 6
- 125000003828 azulenyl group Chemical group 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 229960002715 nicotine Drugs 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 claims description 5
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 claims description 5
- 125000004522 1,3,4-thiadiazol-5-yl group Chemical group S1C=NN=C1* 0.000 claims description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- FHBQJQOZXLTNAR-UHFFFAOYSA-N 3-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,2-benzothiazole Chemical compound C1=CC=C2C(OC3C4CCN(C3)CC4)=NSC2=C1 FHBQJQOZXLTNAR-UHFFFAOYSA-N 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 5
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 5
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims description 5
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims description 5
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims description 5
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 5
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 5
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims description 5
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
- LRQZHEAZRKGYRO-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)quinoline Chemical compound C1=CC=CC2=NC(OC3C4CCN(C3)CC4)=CC=C21 LRQZHEAZRKGYRO-UHFFFAOYSA-N 0.000 claims description 4
- RPAIFTHNSMJQGX-UHFFFAOYSA-M 2-(1-azabicyclo[2.2.2]octan-3-yloxy)quinoxaline;carbanylium;iodide Chemical compound [CH3+].[I-].C1=CC=CC2=NC(OC3C4CCN(C3)CC4)=CN=C21 RPAIFTHNSMJQGX-UHFFFAOYSA-M 0.000 claims description 4
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 229910005965 SO 2 Inorganic materials 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 claims description 3
- BXENYFDBSRHICB-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-3-chloroquinoxaline Chemical compound C1N(CC2)CCC2C1OC1=NC2=CC=CC=C2N=C1Cl BXENYFDBSRHICB-UHFFFAOYSA-N 0.000 claims description 3
- VSKHAHUONMJJFL-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-bromo-1,3-thiazole Chemical compound S1C(Br)=CN=C1OC1C(CC2)CCN2C1 VSKHAHUONMJJFL-UHFFFAOYSA-N 0.000 claims description 3
- NVYFUUNOOKTHMV-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)quinoxaline Chemical compound C1=CC=CC2=NC(OC3C4CCN(C3)CC4)=CN=C21 NVYFUUNOOKTHMV-UHFFFAOYSA-N 0.000 claims description 3
- ISTQAMKJXZTCAM-UHFFFAOYSA-N 3-(3-phenylphenoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(C=1)=CC=CC=1C1=CC=CC=C1 ISTQAMKJXZTCAM-UHFFFAOYSA-N 0.000 claims description 3
- PFRYGKATQCVDFW-UHFFFAOYSA-N 3-[(4-phenylphenyl)methoxy]-1-azabicyclo[2.2.2]octane Chemical compound C1N(CC2)CCC2C1OCC(C=C1)=CC=C1C1=CC=CC=C1 PFRYGKATQCVDFW-UHFFFAOYSA-N 0.000 claims description 3
- ZTVUBKRSTBDFBC-UHFFFAOYSA-N 3-dibenzofuran-2-yloxy-1-azabicyclo[2.2.2]octane Chemical group C1=CC=C2C3=CC(OC4C5CCN(C4)CC5)=CC=C3OC2=C1 ZTVUBKRSTBDFBC-UHFFFAOYSA-N 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims description 3
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- FIDMJKLFOPNZTL-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yloxy)benzotriazole Chemical compound N1=NC2=CC=CC=C2N1OC(C1)C2CCN1CC2 FIDMJKLFOPNZTL-UHFFFAOYSA-N 0.000 claims description 2
- COPKZPSRVDULIN-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,3-benzothiazole Chemical compound C1=CC=C2SC(OC3C4CCN(C3)CC4)=NC2=C1 COPKZPSRVDULIN-UHFFFAOYSA-N 0.000 claims description 2
- ONZZUKINKMKNFG-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,3-benzoxazole Chemical compound C1=CC=C2OC(OC3C4CCN(C3)CC4)=NC2=C1 ONZZUKINKMKNFG-UHFFFAOYSA-N 0.000 claims description 2
- VWUNUDCRVBDVAE-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-1-methylbenzimidazole Chemical compound C1=CC=C2N(C)C(OC3C4CCN(CC4)C3)=NC2=C1 VWUNUDCRVBDVAE-UHFFFAOYSA-N 0.000 claims description 2
- YGRYEAVJUADRGH-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-3-methoxyquinoxaline Chemical compound C1N(CC2)CCC2C1OC1=NC2=CC=CC=C2N=C1OC YGRYEAVJUADRGH-UHFFFAOYSA-N 0.000 claims description 2
- BWNSGMZYAPFBRL-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-(2,4-difluorophenyl)-1,3-thiazole Chemical compound FC1=CC(F)=CC=C1C(S1)=CN=C1OC1C(CC2)CCN2C1 BWNSGMZYAPFBRL-UHFFFAOYSA-N 0.000 claims description 2
- BQVJZWBRVUEZKU-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-(furan-3-yl)-1,3-thiazole Chemical compound C1CN(C2)CCC1C2OC(S1)=NC=C1C=1C=COC=1 BQVJZWBRVUEZKU-UHFFFAOYSA-N 0.000 claims description 2
- RMCHOLPMARHFKR-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-phenyl-1,3,4-thiadiazole Chemical compound C1CN(C2)CCC1C2OC(S1)=NN=C1C1=CC=CC=C1 RMCHOLPMARHFKR-UHFFFAOYSA-N 0.000 claims description 2
- KHJZSFUHZDEQIU-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-phenyl-1,3-thiazole Chemical compound C1CN(C2)CCC1C2OC(S1)=NC=C1C1=CC=CC=C1 KHJZSFUHZDEQIU-UHFFFAOYSA-N 0.000 claims description 2
- PTPLMYRMZXCHSZ-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-pyridin-3-yl-1,3-thiazole Chemical compound C1CN(C2)CCC1C2OC(S1)=NC=C1C1=CC=CN=C1 PTPLMYRMZXCHSZ-UHFFFAOYSA-N 0.000 claims description 2
- FPVAPJYIZHSJKF-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-thiophen-2-yl-1,3,4-thiadiazole Chemical compound C1CN(C2)CCC1C2OC(S1)=NN=C1C1=CC=CS1 FPVAPJYIZHSJKF-UHFFFAOYSA-N 0.000 claims description 2
- WENRZTCKEUNEMA-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-thiophen-2-yl-1,3-thiazole Chemical compound C1CN(C2)CCC1C2OC(S1)=NC=C1C1=CC=CS1 WENRZTCKEUNEMA-UHFFFAOYSA-N 0.000 claims description 2
- GCNWMXJESTZDJB-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-thiophen-3-yl-1,3-thiazole Chemical compound C1CN(C2)CCC1C2OC(S1)=NC=C1C=1C=CSC=1 GCNWMXJESTZDJB-UHFFFAOYSA-N 0.000 claims description 2
- JVLOHDNSLWPUJF-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-6-chloro-1,3-benzothiazole Chemical compound C1N(CC2)CCC2C1OC1=NC2=CC=C(Cl)C=C2S1 JVLOHDNSLWPUJF-UHFFFAOYSA-N 0.000 claims description 2
- AUVDLTULQQPZDF-UHFFFAOYSA-M 2-(1-azabicyclo[2.2.2]octan-3-yloxy)quinoline;carbanylium;iodide Chemical compound [CH3+].[I-].C1=CC=CC2=NC(OC3C4CCN(C3)CC4)=CC=C21 AUVDLTULQQPZDF-UHFFFAOYSA-M 0.000 claims description 2
- NMFVGYWXADHCBK-UHFFFAOYSA-N 3-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-phenyl-1,2,4-thiadiazole Chemical compound C1CN(C2)CCC1C2OC(N=1)=NSC=1C1=CC=CC=C1 NMFVGYWXADHCBK-UHFFFAOYSA-N 0.000 claims description 2
- ONNLEVOYDBCRKS-UHFFFAOYSA-N 3-(2,3-dihydro-1h-inden-5-yloxy)-1-azabicyclo[2.2.2]octane Chemical compound C1N(CC2)CCC2C1OC1=CC=C2CCCC2=C1 ONNLEVOYDBCRKS-UHFFFAOYSA-N 0.000 claims description 2
- ZBDIBRKIGUGEEP-UHFFFAOYSA-N 3-(2-phenylphenoxy)-1-azabicyclo[2.2.2]octane Chemical group C1CN(C2)CCC1C2OC1=CC=CC=C1C1=CC=CC=C1 ZBDIBRKIGUGEEP-UHFFFAOYSA-N 0.000 claims description 2
- HYYHQFCZRLZVEX-UHFFFAOYSA-N 3-(3,4,5-trichlorothiophen-2-yl)oxy-1-azabicyclo[2.2.2]octane Chemical group ClC1=C(Cl)SC(OC2C3CCN(CC3)C2)=C1Cl HYYHQFCZRLZVEX-UHFFFAOYSA-N 0.000 claims description 2
- BCIOGGPNGDFPBO-UHFFFAOYSA-N 3-(4-phenylphenoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(C=C1)=CC=C1C1=CC=CC=C1 BCIOGGPNGDFPBO-UHFFFAOYSA-N 0.000 claims description 2
- OQMAYTGWZKXAME-UHFFFAOYSA-N 3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)-1-azabicyclo[2.2.2]octane Chemical compound C1N(CC2)CCC2C1OC1=CC=C(CCCC2)C2=C1 OQMAYTGWZKXAME-UHFFFAOYSA-N 0.000 claims description 2
- MCAXDSHKPBDHIW-UHFFFAOYSA-N 3-(6-chloropyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound N1=NC(Cl)=CC=C1OC1C(CC2)CCN2C1 MCAXDSHKPBDHIW-UHFFFAOYSA-N 0.000 claims description 2
- FWJYJIHEZKZYMF-UHFFFAOYSA-N 3-(6-phenylpyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CC=C1 FWJYJIHEZKZYMF-UHFFFAOYSA-N 0.000 claims description 2
- HMJIRHSCISEZOV-UHFFFAOYSA-N 3-(6-pyridin-3-ylpyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CN=C1 HMJIRHSCISEZOV-UHFFFAOYSA-N 0.000 claims description 2
- BGMCIWWSQXKNSS-UHFFFAOYSA-N 3-(6-thiophen-2-ylpyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CS1 BGMCIWWSQXKNSS-UHFFFAOYSA-N 0.000 claims description 2
- WDLZVIQQVWKVEO-UHFFFAOYSA-N 3-(6-thiophen-3-ylpyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C=1C=CSC=1 WDLZVIQQVWKVEO-UHFFFAOYSA-N 0.000 claims description 2
- IIDQULJVLLYOIG-UHFFFAOYSA-N 3-[6-(furan-2-yl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CO1 IIDQULJVLLYOIG-UHFFFAOYSA-N 0.000 claims description 2
- PYLFURFAUASCCK-UHFFFAOYSA-N 3-[6-(furan-3-yl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C=1C=COC=1 PYLFURFAUASCCK-UHFFFAOYSA-N 0.000 claims description 2
- ZDNDANLSNOBCPJ-UHFFFAOYSA-N 3-naphthalen-2-yloxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=CC2=CC(OC3C4CCN(C3)CC4)=CC=C21 ZDNDANLSNOBCPJ-UHFFFAOYSA-N 0.000 claims description 2
- KJIFATUUESTGPL-UHFFFAOYSA-N 6-(1-azabicyclo[2.2.2]octan-3-yloxy)quinoline Chemical compound N1=CC=CC2=CC(OC3C4CCN(C3)CC4)=CC=C21 KJIFATUUESTGPL-UHFFFAOYSA-N 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 206010002660 Anoxia Diseases 0.000 claims description 2
- 241000976983 Anoxia Species 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 241000208125 Nicotiana Species 0.000 claims description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000005374 Poisoning Diseases 0.000 claims description 2
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims description 2
- 208000005107 Premature Birth Diseases 0.000 claims description 2
- 206010036590 Premature baby Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010052276 Pseudodementia Diseases 0.000 claims description 2
- 208000022372 Reading disease Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000007953 anoxia Effects 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 229960003920 cocaine Drugs 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 229960002069 diamorphine Drugs 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 206010013932 dyslexia Diseases 0.000 claims description 2
- 230000002650 habitual effect Effects 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 2
- 230000000938 luteal effect Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 229940005483 opioid analgesics Drugs 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 206010036596 premature ejaculation Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 230000020341 sensory perception of pain Effects 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 15
- 206010049119 Emotional distress Diseases 0.000 claims 3
- 230000009429 distress Effects 0.000 claims 3
- 102000034337 acetylcholine receptors Human genes 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- PQKMYDONPUPYNY-UHFFFAOYSA-N 6-(1-azabicyclo[2.2.2]octan-3-yloxy)-2-phenylimidazo[1,2-b]pyridazine Chemical group C1CN(C2)CCC1C2OC(=NN1C=2)C=CC1=NC=2C1=CC=CC=C1 PQKMYDONPUPYNY-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract description 8
- 230000001713 cholinergic effect Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 230000002124 endocrine Effects 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 18
- 125000005843 halogen group Chemical group 0.000 description 17
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 9
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 239000001530 fumaric acid Substances 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 6
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000009660 Cholinergic Receptors Human genes 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 4
- 108050004812 Dopamine receptor Proteins 0.000 description 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 201000009032 substance abuse Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- JVAOFRWRHUBKQC-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-3-chloroquinoxaline (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=NC2=CC=CC=C2N=C1Cl JVAOFRWRHUBKQC-WLHGVMLRSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000000035 biogenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- KQVVHCZXIWWDKE-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-(6-chloropyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound OC(=O)\C=C\C(O)=O.N1=NC(Cl)=CC=C1OC1C(CC2)CCN2C1 KQVVHCZXIWWDKE-WLHGVMLRSA-N 0.000 description 2
- YZVSCZHAMXTFNT-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-(6-phenylpyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CC=C1 YZVSCZHAMXTFNT-WLHGVMLRSA-N 0.000 description 2
- VDAYOSQIRJFMQQ-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-(6-thiophen-3-ylpyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=N1)=CC=C1C=1C=CSC=1 VDAYOSQIRJFMQQ-WLHGVMLRSA-N 0.000 description 2
- LRFYCQRVOUVFCX-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(furan-2-yl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CO1 LRFYCQRVOUVFCX-WLHGVMLRSA-N 0.000 description 2
- FLLHVUQDGZTZGR-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-naphthalen-2-yloxy-1-azabicyclo[2.2.2]octane Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=CC2=CC(OC3C4CCN(C3)CC4)=CC=C21 FLLHVUQDGZTZGR-WLHGVMLRSA-N 0.000 description 2
- TYEWAAMGGWYJNY-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-dibenzofuran-2-yloxy-1-azabicyclo[2.2.2]octane Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2C3=CC(OC4C5CCN(C4)CC5)=CC=C3OC2=C1 TYEWAAMGGWYJNY-WLHGVMLRSA-N 0.000 description 2
- VEAUAPTZPOACSC-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,3-benzothiazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2SC(OC3C4CCN(C3)CC4)=NC2=C1 VEAUAPTZPOACSC-WLHGVMLRSA-N 0.000 description 2
- YXYGFQMNGSNDDT-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-1-methylbenzimidazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2N(C)C(OC3C4CCN(CC4)C3)=NC2=C1 YXYGFQMNGSNDDT-WLHGVMLRSA-N 0.000 description 2
- YZYRHVNZLQBWNQ-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-(2,4-difluorophenyl)-1,3-thiazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC(F)=CC=C1C(S1)=CN=C1OC1C(CC2)CCN2C1 YZYRHVNZLQBWNQ-WLHGVMLRSA-N 0.000 description 2
- GGVBVLIHTBOYDQ-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-phenyl-1,3-thiazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NC=C1C1=CC=CC=C1 GGVBVLIHTBOYDQ-WLHGVMLRSA-N 0.000 description 2
- XCBDLWVCLSVQKJ-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-thiophen-2-yl-1,3-thiazole;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NC=C1C1=CC=CS1 XCBDLWVCLSVQKJ-WLHGVMLRSA-N 0.000 description 2
- KQKHVGYDJKESPX-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-thiophen-3-yl-1,3,4-thiadiazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NN=C1C=1C=CSC=1 KQKHVGYDJKESPX-WLHGVMLRSA-N 0.000 description 2
- UYMMKRJRQOPBHI-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)quinoline (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=CC2=NC(OC3C4CCN(C3)CC4)=CC=C21 UYMMKRJRQOPBHI-WLHGVMLRSA-N 0.000 description 2
- IOQYZJOXIDIJCG-WLHGVMLRSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)quinoxaline (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=CC2=NC(OC3C4CCN(C3)CC4)=CN=C21 IOQYZJOXIDIJCG-WLHGVMLRSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- GFNQBXJJEDJCIA-UHFFFAOYSA-M 3-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,2-benzothiazole;carbanylium;iodide Chemical compound [CH3+].[I-].C1=CC=C2C(OC3C4CCN(C3)CC4)=NSC2=C1 GFNQBXJJEDJCIA-UHFFFAOYSA-M 0.000 description 2
- NWXJCZHPCMOVFY-WLHGVMLRSA-N 3-(6-bromopyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.N1=NC(Br)=CC=C1OC1C(CC2)CCN2C1 NWXJCZHPCMOVFY-WLHGVMLRSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- ALAWEXMYGNDINJ-WLHGVMLRSA-N 6-(1-azabicyclo[2.2.2]octan-3-yloxy)-2-phenylimidazo[1,2-b]pyridazine (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(=NN1C=2)C=CC1=NC=2C1=CC=CC=C1 ALAWEXMYGNDINJ-WLHGVMLRSA-N 0.000 description 2
- SIJBDWPVNAYVGY-UHFFFAOYSA-N CC1(C)OCCO1 Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 description 2
- HEDYXMHGMMWNBO-UHFFFAOYSA-N CC1(C)SCCS1 Chemical compound CC1(C)SCCS1 HEDYXMHGMMWNBO-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- SSAHZJFVEVAMIQ-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1=CC=C2OC(OC3C4CCN(C3)CC4)=NC2=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2OC(OC3C4CCN(C3)CC4)=NC2=C1 SSAHZJFVEVAMIQ-WLHGVMLRSA-N 0.000 description 2
- SLOIQLYBYINVIH-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=1)=NSC=1C1=CC=CC=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=1)=NSC=1C1=CC=CC=C1 SLOIQLYBYINVIH-WLHGVMLRSA-N 0.000 description 2
- MSCAVTCVXAGXQB-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CS1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CS1 MSCAVTCVXAGXQB-WLHGVMLRSA-N 0.000 description 2
- QCEYEEQQIIEXEE-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=N1)=CC=C1C=1C=COC=1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=N1)=CC=C1C=1C=COC=1 QCEYEEQQIIEXEE-WLHGVMLRSA-N 0.000 description 2
- YENLQNQFHMAKES-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NC=C1C1=CC=CN=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NC=C1C1=CC=CN=C1 YENLQNQFHMAKES-WLHGVMLRSA-N 0.000 description 2
- PZZZLZGHKGFXIP-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NC=C1C=1C=COC=1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NC=C1C=1C=COC=1 PZZZLZGHKGFXIP-WLHGVMLRSA-N 0.000 description 2
- MZPQPOOVQDJBMJ-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NC=C1C=1C=CSC=1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NC=C1C=1C=CSC=1 MZPQPOOVQDJBMJ-WLHGVMLRSA-N 0.000 description 2
- CSXAKOPEZRKZPA-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NN=C1C1=CC=CC=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(S1)=NN=C1C1=CC=CC=C1 CSXAKOPEZRKZPA-WLHGVMLRSA-N 0.000 description 2
- XAZZJDBSKWCDTE-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=CC=C(CCCC2)C2=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=CC=C(CCCC2)C2=C1 XAZZJDBSKWCDTE-WLHGVMLRSA-N 0.000 description 2
- YDKMCHISCXVXAK-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=CC=C2CCCC2=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=CC=C2CCCC2=C1 YDKMCHISCXVXAK-WLHGVMLRSA-N 0.000 description 2
- MJNAMNYMAHBQPI-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=NC2=CC=C(Cl)C=C2S1 Chemical compound OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=NC2=CC=C(Cl)C=C2S1 MJNAMNYMAHBQPI-WLHGVMLRSA-N 0.000 description 2
- PSIOHIUITGQTHL-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=NC2=CC=CC=C2N=C1OC Chemical compound OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OC1=NC2=CC=CC=C2N=C1OC PSIOHIUITGQTHL-WLHGVMLRSA-N 0.000 description 2
- HCTMTMUACAWNCI-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OCC(C=C1)=CC=C1C1=CC=CC=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1N(CC2)CCC2C1OCC(C=C1)=CC=C1C1=CC=CC=C1 HCTMTMUACAWNCI-WLHGVMLRSA-N 0.000 description 2
- GINPHDLBXUZQQX-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.N1=CC=CC2=CC(OC3C4CCN(C3)CC4)=CC=C21 Chemical compound OC(=O)\C=C\C(O)=O.N1=CC=CC2=CC(OC3C4CCN(C3)CC4)=CC=C21 GINPHDLBXUZQQX-WLHGVMLRSA-N 0.000 description 2
- SDMYWBUOYWADOV-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.N1=NC2=CC=CC=C2N1OC(C1)C2CCN1CC2 Chemical compound OC(=O)\C=C\C(O)=O.N1=NC2=CC=CC=C2N1OC(C1)C2CCN1CC2 SDMYWBUOYWADOV-WLHGVMLRSA-N 0.000 description 2
- XVXBXFCVRSCZOZ-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.S1C(Br)=CN=C1OC1C(CC2)CCN2C1 Chemical compound OC(=O)\C=C\C(O)=O.S1C(Br)=CN=C1OC1C(CC2)CCN2C1 XVXBXFCVRSCZOZ-WLHGVMLRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- PEHSSTUGJUBZBI-UHFFFAOYSA-N indan-5-ol Chemical compound OC1=CC=C2CCCC2=C1 PEHSSTUGJUBZBI-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical class [H]C([H])([H])* 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- ZKRSYCGPZSXTHX-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-(6-pyridin-3-ylpyridazin-3-yl)oxy-1-azabicyclo[2.2.2]octane Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CN=C1 ZKRSYCGPZSXTHX-WLHGVMLRSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- QYIMSPSDBYKPPY-RSKUXYSASA-N (S)-2,3-epoxysqualene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CC[C@@H]1OC1(C)C QYIMSPSDBYKPPY-RSKUXYSASA-N 0.000 description 1
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- HLQZCRVEEQKNMS-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylbenzene Chemical compound C1=CC(CCl)=CC=C1C1=CC=CC=C1 HLQZCRVEEQKNMS-UHFFFAOYSA-N 0.000 description 1
- VSEROABGEVRIRY-UHFFFAOYSA-N 1-(chloromethyl)benzotriazole Chemical compound C1=CC=C2N(CCl)N=NC2=C1 VSEROABGEVRIRY-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- WZXXZHONLFRKGG-UHFFFAOYSA-N 2,3,4,5-tetrachlorothiophene Chemical compound ClC=1SC(Cl)=C(Cl)C=1Cl WZXXZHONLFRKGG-UHFFFAOYSA-N 0.000 description 1
- SPSSDDOTEZKOOV-UHFFFAOYSA-N 2,3-dichloroquinoxaline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=NC2=C1 SPSSDDOTEZKOOV-UHFFFAOYSA-N 0.000 description 1
- XIBIQFJKUZZLLX-UHFFFAOYSA-N 2,5-dibromo-1,3-thiazole Chemical compound BrC1=CN=C(Br)S1 XIBIQFJKUZZLLX-UHFFFAOYSA-N 0.000 description 1
- QDZGJGWDGLHVNK-UHFFFAOYSA-N 2,6-dichloro-1,3-benzothiazole Chemical compound C1=C(Cl)C=C2SC(Cl)=NC2=C1 QDZGJGWDGLHVNK-UHFFFAOYSA-N 0.000 description 1
- CHZXTOCAICMPQR-UHFFFAOYSA-N 2-(2-bromoethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCBr)C(=O)C2=C1 CHZXTOCAICMPQR-UHFFFAOYSA-N 0.000 description 1
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 1
- BSQLQMLFTHJVKS-UHFFFAOYSA-N 2-chloro-1,3-benzothiazole Chemical compound C1=CC=C2SC(Cl)=NC2=C1 BSQLQMLFTHJVKS-UHFFFAOYSA-N 0.000 description 1
- BBVQDWDBTWSGHQ-UHFFFAOYSA-N 2-chloro-1,3-benzoxazole Chemical compound C1=CC=C2OC(Cl)=NC2=C1 BBVQDWDBTWSGHQ-UHFFFAOYSA-N 0.000 description 1
- UXZYKSFMGDWHGJ-UHFFFAOYSA-N 2-chloro-1-methylbenzimidazole Chemical compound C1=CC=C2N(C)C(Cl)=NC2=C1 UXZYKSFMGDWHGJ-UHFFFAOYSA-N 0.000 description 1
- ASSPGHHANNDMET-UHFFFAOYSA-N 2-chloro-5-phenyl-1,3,4-thiadiazole Chemical compound S1C(Cl)=NN=C1C1=CC=CC=C1 ASSPGHHANNDMET-UHFFFAOYSA-N 0.000 description 1
- DRDNOLRPUJJPCU-UHFFFAOYSA-N 2-chloro-5-thiophen-3-yl-1,3,4-thiadiazole Chemical compound S1C(Cl)=NN=C1C1=CSC=C1 DRDNOLRPUJJPCU-UHFFFAOYSA-N 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- BYHVGQHIAFURIL-UHFFFAOYSA-N 2-chloroquinoxaline Chemical compound C1=CC=CC2=NC(Cl)=CN=C21 BYHVGQHIAFURIL-UHFFFAOYSA-N 0.000 description 1
- HGIDRHWWNZRUEP-UHFFFAOYSA-N 2-hydroxydibenzofuran Chemical compound C1=CC=C2C3=CC(O)=CC=C3OC2=C1 HGIDRHWWNZRUEP-UHFFFAOYSA-N 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- 229940061334 2-phenylphenol Drugs 0.000 description 1
- VQAFMTSSCUETHA-UHFFFAOYSA-N 3,6-dibromopyridazine Chemical compound BrC1=CC=C(Br)N=N1 VQAFMTSSCUETHA-UHFFFAOYSA-N 0.000 description 1
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
- WEPHBUZIQDDHMG-WLHGVMLRSA-N 3-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,2-benzothiazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2C(OC3C4CCN(C3)CC4)=NSC2=C1 WEPHBUZIQDDHMG-WLHGVMLRSA-N 0.000 description 1
- BCPVKLRBQLRWDQ-UHFFFAOYSA-N 3-chloro-1,2-benzothiazole Chemical compound C1=CC=C2C(Cl)=NSC2=C1 BCPVKLRBQLRWDQ-UHFFFAOYSA-N 0.000 description 1
- ZGROIHXQCKYCPT-UHFFFAOYSA-N 3-chloro-5-phenyl-1,2,4-thiadiazole Chemical compound ClC1=NSC(C=2C=CC=CC=2)=N1 ZGROIHXQCKYCPT-UHFFFAOYSA-N 0.000 description 1
- BUBRFWDEAVIFMV-UHFFFAOYSA-N 3-chloro-6-phenylpyridazine Chemical compound N1=NC(Cl)=CC=C1C1=CC=CC=C1 BUBRFWDEAVIFMV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NYIVWTWKIQOBKO-UHFFFAOYSA-N 4-phenanthren-3-ylbutanoic acid Chemical compound C1=CC=C2C3=CC(CCCC(=O)O)=CC=C3C=CC2=C1 NYIVWTWKIQOBKO-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- UMKXSOXZAXIOPJ-UHFFFAOYSA-N 5,6,7,8-tetrahydro-2-naphthol Chemical compound C1CCCC2=CC(O)=CC=C21 UMKXSOXZAXIOPJ-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- FPWMERDSYDEJOP-UHFFFAOYSA-N 6-chloro-2-phenylimidazo[1,2-b]pyridazine Chemical compound C=1N2N=C(Cl)C=CC2=NC=1C1=CC=CC=C1 FPWMERDSYDEJOP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000272079 Bungarus multicinctus Species 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- LWLSVNFEVKJDBZ-UHFFFAOYSA-N N-[4-(trifluoromethoxy)phenyl]-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide Chemical compound FC(OC1=CC=C(C=C1)NC(=O)N1CCC(CC1)CC1=CC(=CC=C1)OC1=NC=C(C=C1)C(F)(F)F)(F)F LWLSVNFEVKJDBZ-UHFFFAOYSA-N 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- RTYZVUVJINSSHA-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(C=C1)=CC=C1C1=CC=CC=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC(C=C1)=CC=C1C1=CC=CC=C1 RTYZVUVJINSSHA-WLHGVMLRSA-N 0.000 description 1
- MZZCWBVIHKPBAX-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC1=CC=CC=C1C1=CC=CC=C1 Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C2)CCC1C2OC1=CC=CC=C1C1=CC=CC=C1 MZZCWBVIHKPBAX-WLHGVMLRSA-N 0.000 description 1
- QYIMSPSDBYKPPY-UHFFFAOYSA-N OS Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC1OC1(C)C QYIMSPSDBYKPPY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- UBXYXCRCOKCZIT-UHFFFAOYSA-N biphenyl-3-ol Chemical compound OC1=CC=CC(C=2C=CC=CC=2)=C1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- IHJFCKMAQSYVJG-UHFFFAOYSA-N dichloromethane iodomethane Chemical compound IC.ClCCl IHJFCKMAQSYVJG-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- OVYWMEWYEJLIER-UHFFFAOYSA-N quinolin-6-ol Chemical compound N1=CC=CC2=CC(O)=CC=C21 OVYWMEWYEJLIER-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- BZWKPZBXAMTXNQ-UHFFFAOYSA-N sulfurocyanidic acid Chemical compound OS(=O)(=O)C#N BZWKPZBXAMTXNQ-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201208 | 2002-08-14 | ||
| DKPA200201472 | 2002-10-02 | ||
| PCT/DK2003/000538 WO2004016608A1 (en) | 2002-08-14 | 2003-08-13 | Novel quinuclidine derivatives and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538187A true JP2005538187A (ja) | 2005-12-15 |
| JP2005538187A5 JP2005538187A5 (https=) | 2006-09-21 |
Family
ID=31889349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005502013A Pending JP2005538187A (ja) | 2002-08-14 | 2003-08-13 | 新規キヌクリジン誘導体及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20050245567A1 (https=) |
| EP (2) | EP1532144B1 (https=) |
| JP (1) | JP2005538187A (https=) |
| KR (1) | KR20050055711A (https=) |
| CN (1) | CN100513406C (https=) |
| AT (1) | ATE384720T1 (https=) |
| AU (1) | AU2003250322B2 (https=) |
| BR (1) | BR0313153A (https=) |
| CA (1) | CA2493245A1 (https=) |
| DE (1) | DE60318860T2 (https=) |
| IL (1) | IL166254A0 (https=) |
| IS (1) | IS7742A (https=) |
| MX (1) | MXPA05001702A (https=) |
| NO (1) | NO20051264L (https=) |
| NZ (1) | NZ538058A (https=) |
| PL (1) | PL375533A1 (https=) |
| RU (1) | RU2323217C2 (https=) |
| WO (1) | WO2004016608A1 (https=) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048885B2 (en) | 2005-12-16 | 2011-11-01 | Novartis Ag | Organic compounds |
| US8173667B2 (en) | 2005-10-21 | 2012-05-08 | Novartis Ag | 1-aza-bicycloalkyl derivatives |
| US8236803B2 (en) | 2002-09-04 | 2012-08-07 | Novartis Ag | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists |
| US8609662B2 (en) | 2004-07-14 | 2013-12-17 | Novartis Ag | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases |
| US8759346B2 (en) | 2005-12-16 | 2014-06-24 | Novartis Ag | Organic compounds |
| US8933090B2 (en) | 2004-06-18 | 2015-01-13 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6262265A (ja) * | 1985-09-13 | 1987-03-18 | Hitachi Ltd | 復水器自動検査補修システム |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| WO2004083388A2 (en) | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| DE602004031124D1 (de) | 2003-08-13 | 2011-03-03 | Neurosearch As | Neue chinuklidinderivative und deren pharmazeutische verwendung |
| US20050137203A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
| US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050245531A1 (en) * | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US7241773B2 (en) | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
| US20050137398A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
| US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
| EP1824848A1 (en) * | 2004-12-10 | 2007-08-29 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US7365193B2 (en) | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| US20050171079A1 (en) * | 2004-02-04 | 2005-08-04 | Schrimpf Michael R. | Amino-substituted tricyclic derivatives and methods of use |
| SE0400970D0 (sv) * | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| RU2418797C2 (ru) * | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| AU2006295397A1 (en) * | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| FR2904002A1 (fr) * | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| CN102573842A (zh) * | 2009-07-23 | 2012-07-11 | 诺瓦提斯公司 | 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途 |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| AR081402A1 (es) | 2010-05-17 | 2012-08-29 | Envivo Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato |
| CN103180321A (zh) | 2010-09-23 | 2013-06-26 | Abbvie公司 | 氮杂金刚烷衍生物的一水合物 |
| US20120220729A1 (en) * | 2011-02-28 | 2012-08-30 | Boehringer Ingelheim International Gmbh | Liquid phase separation of plasmid dna isoforms and topoisomers |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| BR112015016992A8 (pt) * | 2013-01-15 | 2018-01-23 | Novartis Ag | uso de agonistas do receptor alfa 7 nicotínico de acetilcolina |
| CN105263492B (zh) * | 2013-01-15 | 2018-04-10 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用 |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| WO2016100184A1 (en) | 2014-12-16 | 2016-06-23 | Forum Pharmaceuticals, Inc. | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| MX2017016231A (es) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. |
| WO2017027600A1 (en) | 2015-08-12 | 2017-02-16 | Forum Pharmaceuticals, Inc. | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3534053A (en) * | 1967-05-24 | 1970-10-13 | American Home Prod | Quinuclidine derivatives |
| DE2502916A1 (de) * | 1974-03-05 | 1975-09-11 | Vni Chimiko Farmazewtitscheski | (chinuklidyl-3)-diaryl(heteryl) karbinole, ihre salze und verfahren zu deren herstellung |
| JPH0193585A (ja) * | 1987-08-04 | 1989-04-12 | John Wyeth & Bros Ltd | 新規エーテル化合物 |
| JPH01153662A (ja) * | 1986-12-10 | 1989-06-15 | Bayer Ag | 置換された塩基性２−アミノテトラリン類 |
| JPH0228180A (ja) * | 1988-04-01 | 1990-01-30 | Sankyo Co Ltd | カルバペネム誘導体 |
| JPH02129186A (ja) * | 1988-10-03 | 1990-05-17 | Beecham Group Plc | 新規化合物、その製法及びそれを含む医薬組成物 |
| JPH04226981A (ja) * | 1990-05-19 | 1992-08-17 | Boehringer Ingelheim Kg | 二環式の１−アザ−シクロアルカン化合物 |
| JPH0559050A (ja) * | 1991-02-01 | 1993-03-09 | Akzo Nv | ３−キヌクリジン誘導体 |
| JPH07503463A (ja) * | 1992-01-28 | 1995-04-13 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | カルシウムチャンネル拮抗薬としてのアザビシクロ化合物 |
| JPH0840999A (ja) * | 1994-08-04 | 1996-02-13 | Yamanouchi Pharmaceut Co Ltd | フルオロインダン誘導体 |
| JPH09512804A (ja) * | 1994-05-06 | 1997-12-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５−ｈｔ１ｄアンタゴニストとして有用なビフェニルカルボキシアミド類 |
| WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| JP2001514176A (ja) * | 1997-08-27 | 2001-09-11 | ファイザー・プロダクツ・インク | Ｎｏｓ阻害剤であり縮合環置換基を含む２−アミノピリジン類 |
| JP2002030084A (ja) * | 2000-07-18 | 2002-01-29 | Mitsubishi Pharma Corp | １−アザビシクロアルカン化合物およびその医薬用途 |
| WO2002044176A1 (en) * | 2000-12-01 | 2002-06-06 | Neurosearch A/S | 3-substituted quinuclidines and their use as nicotinic agonists |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5405853A (en) * | 1987-09-10 | 1995-04-11 | Merck Sharpe & Dohme Ltd. | Thiadiazoles useful in the treatment of senile dementia |
| IT1227729B (it) * | 1988-12-23 | 1991-05-06 | Savio Spa | Procedimento e dispositivo per la rimozione delle fibre deteriorate durante il riattacco del filo in un filatoio open-end |
| US5589477A (en) * | 1990-08-31 | 1996-12-31 | Nippon Shinyaku Company, Limited | Pyrimidine derivatives and drugs |
| US5948793A (en) * | 1992-10-09 | 1999-09-07 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release |
| US5998404A (en) * | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5646289A (en) * | 1994-10-24 | 1997-07-08 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| JPH08134067A (ja) * | 1994-11-11 | 1996-05-28 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| US5512574A (en) * | 1994-12-21 | 1996-04-30 | American Home Products Corporation | Quinuclidine and azabicyclo 2.2.1! heptane pyrazinyl ethers as muscarinic agonists |
| US5852037A (en) * | 1995-11-13 | 1998-12-22 | Eli Lilly And Company | Method for treating anxiety |
| JP2000500452A (ja) * | 1995-11-13 | 2000-01-18 | イーライ・リリー・アンド・カンパニー | 不安の処置法 |
| US5763457A (en) * | 1995-11-13 | 1998-06-09 | Eli Lilly And Company | Method for treating anxiety |
| FR2754261B1 (fr) * | 1996-10-08 | 1998-10-30 | Synthelabo | Derives de quinuclidine, leur preparation et leur application en therapeutique |
| WO1998027983A1 (en) * | 1996-12-20 | 1998-07-02 | Novo Nordisk A/S | A method of treating hypercholesterolemia and related disorders |
| FR2772378B1 (fr) * | 1997-12-12 | 2000-02-04 | Synthelabo | Derives d'imidazole, leur preparation et leur application en therapeutique |
-
2003
- 2003-08-13 AU AU2003250322A patent/AU2003250322B2/en not_active Ceased
- 2003-08-13 WO PCT/DK2003/000538 patent/WO2004016608A1/en not_active Ceased
- 2003-08-13 RU RU2005101748/04A patent/RU2323217C2/ru not_active IP Right Cessation
- 2003-08-13 CA CA002493245A patent/CA2493245A1/en not_active Abandoned
- 2003-08-13 CN CNB038190788A patent/CN100513406C/zh not_active Expired - Fee Related
- 2003-08-13 US US10/522,150 patent/US20050245567A1/en not_active Abandoned
- 2003-08-13 JP JP2005502013A patent/JP2005538187A/ja active Pending
- 2003-08-13 DE DE60318860T patent/DE60318860T2/de not_active Expired - Lifetime
- 2003-08-13 AT AT03787742T patent/ATE384720T1/de not_active IP Right Cessation
- 2003-08-13 PL PL03375533A patent/PL375533A1/xx not_active Application Discontinuation
- 2003-08-13 MX MXPA05001702A patent/MXPA05001702A/es active IP Right Grant
- 2003-08-13 EP EP03787742A patent/EP1532144B1/en not_active Expired - Lifetime
- 2003-08-13 BR BR0313153-0A patent/BR0313153A/pt not_active IP Right Cessation
- 2003-08-13 NZ NZ538058A patent/NZ538058A/en not_active IP Right Cessation
- 2003-08-13 KR KR1020057002514A patent/KR20050055711A/ko not_active Ceased
- 2003-08-13 EP EP08100204A patent/EP1905771A3/en not_active Withdrawn
-
2005
- 2005-01-12 IL IL16625405A patent/IL166254A0/xx unknown
- 2005-03-11 NO NO20051264A patent/NO20051264L/no not_active Application Discontinuation
- 2005-03-14 IS IS7742A patent/IS7742A/is unknown
-
2008
- 2008-09-08 US US12/206,302 patent/US20090005390A1/en not_active Abandoned
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3534053A (en) * | 1967-05-24 | 1970-10-13 | American Home Prod | Quinuclidine derivatives |
| DE2502916A1 (de) * | 1974-03-05 | 1975-09-11 | Vni Chimiko Farmazewtitscheski | (chinuklidyl-3)-diaryl(heteryl) karbinole, ihre salze und verfahren zu deren herstellung |
| JPH01153662A (ja) * | 1986-12-10 | 1989-06-15 | Bayer Ag | 置換された塩基性２−アミノテトラリン類 |
| JPH0193585A (ja) * | 1987-08-04 | 1989-04-12 | John Wyeth & Bros Ltd | 新規エーテル化合物 |
| JPH0228180A (ja) * | 1988-04-01 | 1990-01-30 | Sankyo Co Ltd | カルバペネム誘導体 |
| JPH02129186A (ja) * | 1988-10-03 | 1990-05-17 | Beecham Group Plc | 新規化合物、その製法及びそれを含む医薬組成物 |
| JPH04226981A (ja) * | 1990-05-19 | 1992-08-17 | Boehringer Ingelheim Kg | 二環式の１−アザ−シクロアルカン化合物 |
| JPH0559050A (ja) * | 1991-02-01 | 1993-03-09 | Akzo Nv | ３−キヌクリジン誘導体 |
| JPH07503463A (ja) * | 1992-01-28 | 1995-04-13 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | カルシウムチャンネル拮抗薬としてのアザビシクロ化合物 |
| JPH09512804A (ja) * | 1994-05-06 | 1997-12-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５−ｈｔ１ｄアンタゴニストとして有用なビフェニルカルボキシアミド類 |
| JPH0840999A (ja) * | 1994-08-04 | 1996-02-13 | Yamanouchi Pharmaceut Co Ltd | フルオロインダン誘導体 |
| JP2001514176A (ja) * | 1997-08-27 | 2001-09-11 | ファイザー・プロダクツ・インク | Ｎｏｓ阻害剤であり縮合環置換基を含む２−アミノピリジン類 |
| WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| JP2002030084A (ja) * | 2000-07-18 | 2002-01-29 | Mitsubishi Pharma Corp | １−アザビシクロアルカン化合物およびその医薬用途 |
| WO2002044176A1 (en) * | 2000-12-01 | 2002-06-06 | Neurosearch A/S | 3-substituted quinuclidines and their use as nicotinic agonists |
Non-Patent Citations (5)
| Title |
|---|
| JPN6009068278, Ｂｉｏｏｒｇａｎｉｃ ＆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｌｅｔｔｅｒｓ, 1994, Ｖｏｌ．４， Ｎｏ．２４, ｐａｇｅｓ ２８３７−４０ * |
| JPN6009068281, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 1969, Ｖｏｌ．１２， Ｎｏ．３, ｐａｇｅｓ ５２４−５２６ * |
| JPN6009068283, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 1996, Ｖｏｌ．３９， Ｎｏ．１５, ｐａｇｅｓ ２９７１−２９７９ * |
| JPN6009068285, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 1999, Ｖｏｌ．４２， Ｎｏ．７, ｐａｇｅｓ １３０６−１３１１ * |
| JPN6009068288, Ａｎａｌｙｔｉｃａｌ Ｂｉｏｃｈｅｍｉｓｔｒｙ, 1995, Ｖｏｌ．２２６， Ｎｏ．２, ｐａｇｅｓ ２６８−２７８ * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012451B2 (en) | 2002-09-04 | 2015-04-21 | Novartis Ag | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists |
| US9849117B2 (en) | 2002-09-04 | 2017-12-26 | Novartis Ag | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| US8236803B2 (en) | 2002-09-04 | 2012-08-07 | Novartis Ag | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists |
| US9567343B2 (en) | 2002-09-04 | 2017-02-14 | Novartis Ag | Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists |
| US9475811B2 (en) | 2004-06-18 | 2016-10-25 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
| US8933090B2 (en) | 2004-06-18 | 2015-01-13 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
| US8609662B2 (en) | 2004-07-14 | 2013-12-17 | Novartis Ag | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases |
| US9657010B2 (en) | 2004-07-14 | 2017-05-23 | Novartis Ag | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators |
| US8173667B2 (en) | 2005-10-21 | 2012-05-08 | Novartis Ag | 1-aza-bicycloalkyl derivatives |
| US8759346B2 (en) | 2005-12-16 | 2014-06-24 | Novartis Ag | Organic compounds |
| US8637517B2 (en) | 2005-12-16 | 2014-01-28 | Novartis Ag | Organic compounds |
| US9206181B2 (en) | 2005-12-16 | 2015-12-08 | Novartis Ag | 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders |
| US8048885B2 (en) | 2005-12-16 | 2011-11-01 | Novartis Ag | Organic compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60318860D1 (de) | 2008-03-13 |
| AU2003250322A1 (en) | 2004-03-03 |
| NZ538058A (en) | 2006-11-30 |
| CN1675205A (zh) | 2005-09-28 |
| WO2004016608A1 (en) | 2004-02-26 |
| EP1532144A1 (en) | 2005-05-25 |
| ATE384720T1 (de) | 2008-02-15 |
| EP1532144B1 (en) | 2008-01-23 |
| PL375533A1 (en) | 2005-11-28 |
| RU2005101748A (ru) | 2006-01-20 |
| US20090005390A1 (en) | 2009-01-01 |
| EP1905771A3 (en) | 2008-11-26 |
| BR0313153A (pt) | 2005-06-28 |
| KR20050055711A (ko) | 2005-06-13 |
| EP1905771A2 (en) | 2008-04-02 |
| IS7742A (is) | 2005-03-14 |
| NO20051264L (no) | 2005-05-18 |
| IL166254A0 (en) | 2006-01-15 |
| AU2003250322B2 (en) | 2010-01-21 |
| CN100513406C (zh) | 2009-07-15 |
| CA2493245A1 (en) | 2004-02-26 |
| MXPA05001702A (es) | 2005-04-19 |
| US20050245567A1 (en) | 2005-11-03 |
| RU2323217C2 (ru) | 2008-04-27 |
| DE60318860T2 (de) | 2008-05-21 |
| HK1080860A1 (zh) | 2006-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005538187A (ja) | 新規キヌクリジン誘導体及びその使用方法 | |
| US7220741B2 (en) | 1,4-diazabicycloalkane derivatives, their preparation and use | |
| JP2006508109A (ja) | １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用 | |
| US7750011B2 (en) | Diazabicyclic aryl derivatives and their medical use | |
| US7674899B2 (en) | Dimeric azacyclic compounds and their use | |
| JP2008517032A (ja) | 新規なジアザ二環式アリール誘導体及びその医薬用途 | |
| US7652010B2 (en) | Azabicyclic aryl derivatives and their medical use | |
| KR20050062575A (ko) | 신규한 1,4-디아자바이사이클로알칸 유도체, 이의 제법 및용도 | |
| US7223753B2 (en) | Diazabicyclic biaryl derivatives | |
| US7750022B2 (en) | Quinuclidine derivatives and their pharmaceutical use | |
| US7612074B2 (en) | Diazabicyclic aryl derivatives as cholinergy ligands | |
| HK1080860B (en) | Novel quinuclidine derivatives and their use | |
| JP4294958B2 (ja) | 新規２，５−ジアザビシクロ［２．２．１］ヘプタン誘導体 | |
| UA78812C2 (en) | Quinuclidine derivatives and their use | |
| JP2008516930A (ja) | 新規なアザ二環式アリール誘導体及びその医学的な使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060724 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060724 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100413 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100420 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100519 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100921 |